Compare Abeona Therapeutics Inc (ABEO) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Canadian National Railway Co. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Canadian National Railway Co. trades at $122.23 (market cap $74.49B). The key difference: Canadian National Railway Co. is far larger — about 199.5× Abeona Therapeutics Inc's market cap, and Canadian National Railway Co. pays a 2.1% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CNI | |
|---|---|---|
Market Cap | $373.32M | $74.49B |
Sector | Health | Industrials |
52-Week High | $7.23 | $122.78 |
52-Week Low | $4.17 | $90.91 |
Enterprise Value | $228.22M | $89.95B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CNI trades at $122.78, up 1.0% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS in line with expectations at $1.31, following beats in prior quarters, and maintains strong profitability with a 27.23% net income margin. Recent news highlights operational records in propane and grain shipments, alongside a new rail agreement for BHP's Jansen Potash Mine, supporting long-term growth.
The outlook is positive with a consensus price target of $142.33 implying 16% upside, though high valuation multiples and rising debt levels pose risks. Analyst sentiment is mixed with 35% buy ratings, but institutional interest remains steady. Key catalysts include Q2 2026 earnings on July 24, 2026, and execution on new logistics contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
